haemostasis. 3, 4 However, there is no standard dose that reliably treats all bleeding episodes, nor has the most efficacious dose for any given clinical scenario been prospectively identified. [5] [6] [7] [8] [9] [10] [11] [12] Thrombotic risk, unpredictable rFVIIa (eptacog alfa, NovoSeven ® RT, Novo Nordisk A/S) dose requirements, the limited utility of surrogate laboratory markers of clinical response and challenges with patient access to therapy have hampered the adoption of early haemostasis (ie the shortest possible time spent bleeding) as a primary treatment goal. 13, 14 Many years of clinical experience in patients with congenital haemophilia A or B with inhibitors have shown the thrombotic risk of rFVIIa administration to be acceptable, being primarily associated with patients who already possess prothrombotic risk factors. 15, 16 In addition, retrospective analyses have confirmed the acceptable risk profile of initial doses of >240 μg/kg rFVIIa in this population. 17 Variation in real-life treatment protocols is characteristic of ondemand rFVIIa (eptacog alfa) therapy. 5, 18, 19 Early clinical use began as empiric dose-finding; later, prospective clinical studies attempted to show improved efficacy with higher initial doses of rFVIIa. These studies demonstrated inconsistent efficacy and little conclusive evidence of reduction in time to symptom relief. 7, [18] [19] [20] [21] [22] In addition, multiple large retrospective analyses failed to identify a dosing protocol that predictably led to early haemostasis across the spectrum of outpatient bleeding episodes. 15, 19, 20, 23 Current best practices for rFVIIa dosing seek early bleed resolution by considering bleeding site and severity history, thrombotic risk factors, patient adherence and prior treatment response. Despite this, the use of intermittent, titrated dosing of rFVIIa remains prevalent, a practice which may delay haemostasis and result in some patients continuing to actively or (as some have speculated) sub-acutely haemorrhage over many hours. 19, 24, 25 A new bypassing agent, activated eptacog beta (rhFVIIa, LFB SA), has been developed to address this advancing strategy. 26 rhFVIIa is a recombinant human FVIIa manufactured using rPro ® Technology, 27 developed for the treatment of inhibitor-associated BEs. Following a prospective pharmacokinetic and pharmacodynamic dose-ranging study, 28, 29 in which the relationship between Cmax (peak plasma concentration of rhFVIIa) and ex-vivo thrombin generation was quantified in subjects with haemophilia A or B, two initial doses for treatment of acute bleeding episodes (BEs) were chosen for activated eptacog beta (Figures S1
and S2). 28, 29 Subsequently, we conducted the first PERSEPT Trial for the on-demand early treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors and report the results here.
| METHODS
This study received approval by institutional review boards and was conducted in compliance with established good clinical practices as stated in the current Declaration of Helsinki. 30 Written informed consent was obtained from all subjects (or guardians) at the time of their enrolment. This study is registered at www.clinicaltrials.gov (#NCT02020369).
| Eligibility criteria
Male subjects with congenital haemophilia A or B and inhibitors to either FVIII or FIX were eligible for enrolment (inclusion/exclusion criteria are listed in Table 1 ). Demographic and baseline characteristics were collected during study enrolment.
| Study design
PERSEPT 1 was a global, multicentre, open-label, prospective, randomized, cross-over Phase 3 study evaluating the efficacy, safety and immunogenicity of two initial dose regimens (IDR) of rhFVIIa (eptacog beta, activated) for in-clinic or at-home, on-demand treatment of bleeding episodes. Subjects were advised to treat with rhFVIIa as soon as symptoms of bleeding were recognized (within 4 hours). The primary endpoint was therapeutic response to the treatment of mild/ moderate BEs; severe BEs were also evaluated ( Table 2 ). Subjects were randomized 1:1 via web-based computation to a cross-over
Inclusion criteria Exclusion criteria
Male with a diagnosis of congenital haemophilia A or B of any severity Known allergy or sensitivity to rabbits
At least three bleeding episodes of any severity in the past 6 mo Immunosuppressed (CD4 count at screening ≤200/μL), or low platelet count (<100 000/mL) T A B L E 1 Key inclusion and exclusion criteria for the PERSEPT 1 Phase 3 study treatment group by IDR that prescribed dosing intervals through 24-hours using 75 μg/kg or 225 μg/kg of rhFVIIa ( Figure 1 ). IDR crossover occurred every 3 months until study end. The dosing schedule for mild/moderate BEs is depicted in Figure 2 .
The treatment protocol for severe BEs was similar to that for mild/ moderate BEs. The requirements were as follows: same initial dose as current IDR, early first dose treatment at home, the requirement for rhFVIIa administration in a hospital setting and the use of 2-hour dosing/evaluation intervals ( Figure 3 ).
| Efficacy assessment
The primary efficacy endpoint was the successful treatment of a BE 12 hours after initial administration of rhFVIIa and without rebleeding F I G U R E 1 Subject disposition in the study. Subjects received the first infusion of their assigned initial dose regimen (IDR) study medication (either 75 μg/kg or 225 μg/kg) at their local study centre to evaluate for potential adverse events. Following a review of 20 mild/moderate bleeding episodes (BEs) by the data monitoring committee, severe BEs became eligible for study treatment. As some subjects withdrew from the study prior to initiating their second IDR (or did not experience a BE on an IDR), not all 27 subjects were evaluable for efficacy across both IDRs (safety evaluations were available for all 27 subjects, whereas efficacy assessments were available for only 25 subjects on each IDR). Treatment cross-over occurred every 3 months on treatment prior to 24 hours. The subject (and physician, if present) used a haemostasis evaluation scale to assess efficacy as a means of determining need for further treatment at the next-scheduled dose (Table 3) .
Missing assessments at 12 hours were not included in the analysis.
Haemostatic efficacy for each IDR was the success proportion of BEs treated having a satisfactory and sustained therapeutic response.
Thus, a BE could have a satisfactory clinical response at 12 hours, but be deemed a treatment failure if sustained haemostasis at 24 hours was not achieved (Figure 4 ). After 24 hours, subjects followed their primary physician's instructions for follow-up dosing with their regular bypassing agent (rFVIIa or aPCC, activated prothrombin complex concentrate).
| Pain assessment
Subjects used a Visual Analog Scale (VAS) to assess pain on a scale from 0 (no pain) to 100 mm (worst possible pain) at the time of efficacy assessment. A baseline assessment was made immediately prior to the first infusion of study medication for each BE, with subsequent assessments being made during each efficacy evaluation and at 12 and 24 hours.
F I G U R E 2
Mild and moderate bleeding episode (BE) protocol. Subjects were advised to treat a BE as soon as possible, at most within 4 hours of the first sign of any symptoms. Subjects kept detailed diaries of all BEs, treatments and outcomes during the study. Subjects treated in the 75 μg/kg initial dose regimen (IDR) evaluated and recorded efficacy every 3 hours until a satisfactory outcome was achieved. If a satisfactory outcome was achieved prior to the 12-or 24-hour time points, evaluations were also taken at those two time points. Subjects treated in the 225 μg/kg IDR opted to evaluate and record efficacy in their treatment diaries at the 3-hour time point. They then evaluated and recorded efficacy at the 9-hour time point, and every 3 hours thereafter until a satisfactory outcome was achieved. If a satisfactory outcome was achieved prior to the 12-or 24-hour time points, evaluations were also taken at those two time points. If an unsatisfactory response was reported at 24 hours on either IDR, then alternative therapies could be initiated at the discretion of the investigator F I G U R E 3 All possible doses and dosing intervals for treatment of severe bleeding episodes
| Safety assessment
All subjects underwent evaluations, including physical examination, Serum samples to test for antibodies against rhFVIIa and any production-related impurities were collected during the study. Testing for antibodies against rhFVIIa was performed with an electrochemiluminescent assay able to detect all antibody isotypes. If confirmed in a repeat assay, the antibody was then tested for anti-rhFVIIa neutralizing potential.
As rhFVIIa is isolated from the milk of transgenic rabbits, additional assays analysed the subject samples for the development of antibodies specific to host proteins and casein.
| Statistical analysis
Continuous variables were summarized using descriptive statistics 
| Subject Population
Twenty-nine subjects were screened at 13 centres in the US and Europe, with 27 subjects participating ( Figure 1 ). Detailed demographics are listed in Table 4 .
Four hundred and sixty-five mild/moderate BEs and three severe BEs were treated during the study (Table 5 ). The median time on the study for all randomized subjects was 7.5 months (mean:
6.6 months), with the maximum time on study being 9.5 months.
The median number of BEs during the study was 11 per subject.
Where both subject-and physician-reported assessments of efficacy were available (47/465; 10%), there was a 97.9% (46/47) concordance. Two subjects received concomitant ITI therapy during the study. One of these experienced two mild/moderate BEs (neither of which were successfully treated within 12 hours on the 75 μg/kg IDR), and he withdrew from the study after 19 days. The second ITI subject remained on the study for 200 days and experienced a single BE that was successfully treated with 1 infusion of 75 μg/kg rhFVIIa.
| Efficacy
The overall success proportion at 12 hours across both IDRs was 0.887 (88.7% response rate). A higher success proportion (93.2%) was observed in the 225 μg/kg IDR compared to the 75 μg/kg IDR (84.9%).
These success proportions were statistically significant (P<.001, one-sided 0.0125 significance level) ( Table 6 ). Three severe BEs occurred, one was traumatic (intramuscular haemorrhage), and the others were spontaneous (right hip joint and renal haemorrhage). All occurred while being treated with the 225 μg/kg IDR, thus they were treated with the 225 μg/kg severe bleeding protocol ( Figure 3 ). All had a good or excellent response as evaluated by a physician at 12 hours.
| Pain relief
Overall, pain relief paralleled reported efficacy. Twelve hours after initial administration of rhFVIIa, pain decreased in 86.5% and 86.4% of subjects in the 75 μg/kg and 225 μg/kg IDRs respectively ( Figure 6 ). Eight subjects (29.6%) used pain medications, two of whom used opioids.
| Safety
Twelve subjects (44.4%) reported a total of 14 treatment-emergent adverse events (TEAE) ( Table 7) . These were predominantly nonhaemophilia related, mild and self-resolving. The most common TEAEs are listed in Table 8 . Two subjects experienced treatmentrelated TEAEs: 1 (low grade fever) was considered possibly related to rhFVIIa administration, and 1 (injection site discomfort/haematoma) was considered related to rhFVIIa. Two SAEs (considered unrelated to study medication) were observed in a single subject with a prior history of intracranial haemorrhage (ICH). Five days following that subject's final treatment with rhFVIIa, he was hospitalized for severe tonsillitis and 3 days later developed an ICH, which was successfully treated. No SAEs were observed in any other subject and no deaths were reported.
| Immunogenicity
No neutralizing anti-rhFVIIa or specific antihost protein antibodies were observed following 27 first treatment exposures and 469 reexposure events, including pretreatment exposures in 14 of the subjects. Neither allergic responses nor specific antibody development were observed during follow-up lasting up to 9.5 months.
| DISCUSSION
Variations in acute bleeding aetiologies, sites of bleeding, intermittent telephonic guidance and an accumulating disease burden, combine to make at-home treatment difficult in patients with inhibitors. An axiom of haemophilic therapy is that the time spent bleeding impacts short-and long-term outcomes. Convincing studies have demonstrated that delay of treatment initiation during an active bleeding episode impacts the achievement of haemostasis. 31, 33 In addition, multiple lines of evidence suggest that total haeme (iron) accumulation within a haemophilic joint affects the temporal progression of haemophilic arthropathy and may be difficult to detect. [33] [34] [35] [36] Efforts to reduce haeme accumulation in target joints through prophylaxis and/or early haemostasis are most effective in preventing arthropathic progression.
37,38
Eptacog beta is not functionally equivalent to eptacog alfa; the in vitro, ex vivo, preclinical and human pharmacokinetic studies consistently have held rhFVIIa thrombin generation potential to be clinically important at doses less than those reported in the eptacog alfa literature. 29 Molecular characterizations theoretically may provide structural rationale for that difference; research into the effects of molecular differences on relative FVIIa potency is ongoing. 27 Functional distinctions have previously been sought for rFVIIa variants. 39 The efficacy of eptacog beta was similar for spontaneous, traumatic and target joint bleeding episodes. However, the outcome of receiving bypassing agents; it follows that in similar patients with thrombotic risk factors treated with eptacog beta, we would expect a similar incidence of such events. 16, 40, 41 In this study, on-demand, home treatment with activated eptacog beta of an apparently low thrombotic risk population was safe and well tolerated when treated with either IDR.
New and novel molecules are currently under investigation that may, one day, change how we approach preventing BEs in patients with haemophilia and inhibitors. However, despite such potential advancements, haemostatic bypassing agent therapies, which provide an early, rapid thrombin burst at the site of vascular disruption followed by rapid clearance, will remain a mainstay of therapy for acute bleeding in the inhibitor population.
| CONCLUSIONS
The PERSEPT 1 trial of rhFVIIa (activated eptacog beta) demonstrated sustained efficacy and establishes dose-dependent clinically important target times for achievement of haemostasis in mild and moderate bleeding episodes in haemophilia patients with inhibitors.
Although not observed here, it is likely that the thromboembolic risk associated with rhFVIIa will be like that of other FVIIa-containing products. The observed dose response in this study supports clinical decisions that tailor rhFVIIa bypassing therapy to an early haemostasis goal that includes a potentially predictable response across of a range of mild and moderate bleeding episodes. T A B L E 7 Summary of serious adverse events and treatment-emergent adverse events (TEAE-adverse events occurring at any time after study drug exposure) occurring in more than one subject 
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